Gastric Cancer

New findings from N.N. Dong and co-authors describe advances in gastric cancer

Published in Cancer Weekly, February 2nd, 2010

In this recent study, researchers in Jinan, People's Republic of China conducted a study "To investigate the efficacy and safety of oxaliplatin plus oral capecitabine (XELOX) as first-line chemotherapy in elderly patients with advanced gastric cancer (AGC). Forty-four previously untreated patients with AGC aged 70 or older participated in the study."

"They received oxaliplatin 130 mg/m(2) as 2-hour intravenous infusion on day I and oral capecitabine 1000 mg/m(2) twice daily on days 1 to 14 every 3 weeks XELOX. All patients were assessable for toxicity and 41 patients for response. Median age was 75 years (range, 70-83). In total, 215 cycles of XELOX were delivered. The...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (2010-02-02)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry